Entities

Budapest-based venture capital firm investing in technology businesses that address social and environmental problems in Hungary, Central and Eastern Europe and the wider EU. It backs seed and growth companies in healthcare, education, clean technology, recycling and inclusion, combining financial returns with measurable impact. Its portfolio includes EEG cognitive-health screening, digital mental-health care and AI systems for preventing online abuse.

Ingrid Kelly, also published as Ingrid Kelly Spillmann, is a XISTA Science Ventures partner and Brightmind.AI adviser on intellectual property. She has doctoral training in molecular biology at Cambridge and professional experience in patent law, corporate IP and technology transfer. XISTA’s own biography links the full-name identity and expressly names Brightmind.AI among companies she supports.

XISTA Science Ventures is an Austrian venture capital firm investing in early-stage science-based companies across life sciences, AI, digital technology and industrial deep tech. Formerly known as IST cube, it is part of the innovation ecosystem around the Institute of Science and Technology Austria in Klosterneuburg. The venture investment firm is distinct from XISTA’s technology-transfer organization and science park. Its portfolio includes AI model-compression company Ora Computing and neuroscience companies Syntropic Medical, Neurolentech and Solgate. Markus Wanko and Florian Resch are managing partners. The firm reports EUR96 million under management across two venture funds; its first fund raised EUR45 million in 2021. Public portfolio listings include retired companies and require separate review of each company’s current status.

Ora Computing is a Vienna-based deep-tech software company that develops algorithms to compress and optimize large language models for cloud, on-premises and edge deployment. Its platform combines pruning, quantization and training to reduce model memory requirements and inference costs. Quantum physicists Stefan Sack and Raimel Medina founded the company in early 2025; Sack is CEO and Medina is CTO. Ora reports a pre-seed financing in early 2025 and a EUR3.5 million seed round in 2026, co-led by Constructor Capital and Greencode Ventures with participation from foundational investor XISTA Science Ventures. Its team operates across Europe, including Austria, Switzerland and Germany.

Prosoma develops digital mental-health support for people living with cancer. Its Living Well and Living Well Plus products combine mobile programmes based on cognitive behavioural therapy and psycho-oncology with personalised support and tele-coaching to help patients manage stress, anxiety and depression during diagnosis, treatment and recovery. The company works with healthcare providers, insurers and pharmaceutical partners to make this support available alongside oncology care. Founded in 2018, Prosoma describes Living Well as a European Class I medical device and reports reimbursement by numerous German statutory insurers. It announced EUR 4.4 million in pre-Series A financing in January 2025 to expand in the DACH region and United States.

CRB Health Tech is a Spanish venture capital manager founded in 2008, with offices in Madrid and Barcelona. Its earlier funds backed biotechnology and medical-device companies; its third fund focuses on digital health, including AI-assisted diagnostics, digital therapeutics, remote care, healthcare data platforms and software that improves clinical operations. The firm invests in seed and Series A companies in Spain and Europe, with initial tickets of EUR 500,000 to EUR 1.5 million and follow-on capacity of up to EUR 4–5 million per company. CRB combines investment experience with clinical, pharmaceutical and healthcare-technology expertise to help companies commercialise and scale their products. Its Digital Health III fund reached a EUR 50 million final close announced in May 2026.

Ubotica Technologies is a Dublin-based space technology company developing AI that processes Earth observation data aboard satellites and coordinates sensing across orbit and ground. Its CogniSAT technology enables onboard analysis, while Live Maritime Intelligence combines satellite observations and vessel tracking to identify maritime risks and direct further surveillance. The company works with ESA and NASA’s Jet Propulsion Laboratory and has offices in Ireland, Spain and the Netherlands. Its official releases identify 2017 as its founding year, although a later founder interview refers to involvement from 2016. It announced a EUR4 million seed financing in May 2022 and USD11 million financing in June 2026.

Migrevention is an Estonian digital health company developing connected software for headache and migraine care. Its free Headache App records attacks, symptoms, triggers and medication use, produces reports for appointments and flags possible medication overuse. The company describes the diary as a CE-marked Class I medical device. Its Patient Manager dashboard gives clinicians a longitudinal view of patients, supports remote monitoring and messaging, and connects patient records to structured care workflows. Founded in 2020, Migrevention also supports clinical research using headache data and is developing a digital chronic pain clinic through a research project running from 2024 to 2027.

Mobio Interactive develops AI-assisted mental-health measurement and digital therapeutic software. Its platform uses computer vision and remote photoplethysmography to analyse physiological signals from a short smartphone-camera recording, producing measures of psychological stress without a wearable. Its Dawn DTx platform combines this monitoring with personalised neurobehavioural and mindfulness programmes for healthcare providers, insurers, pharmaceutical partners and individuals. Founded in 2015, the company conducts clinical studies with health and research institutions and offers content in multiple languages. Mobio reports CE MDR Class I status for Dawn DTx. Its longer-term work spans precision psychiatry, remote care and research on mental-health and chronic-illness outcomes.

Zoundream develops AI and sound-recognition software that analyses infant cries and vocalisations to help parents understand babies’ needs. Founded in 2019 and based in Basel and Barcelona, the company licenses its technology for integration into connected baby monitors and other infant-care products, including products from Philips Avent, Maxi-Cosi and Motorola Nursery. It also works with hospitals on research into acoustic biomarkers that could support earlier screening of neurodevelopmental conditions and other infant health problems. These clinical screening applications remain under study, alongside its commercial cry-analysis technology. Zoundream announced a EUR 4 million seed round in September 2025.

Published in Orbit’s combined Venture Partners and Experts in Residence section; the site also lists Chief Strategy Officer, DDB Chicago. The section does not distinguish individual venture partner versus expert status unless stated explicitly.

Walter Greenleaf is a behavioral neuroscientist and medical-technology developer whose Stanford Virtual Human Interaction Lab biography describes research in virtual reality, digital health and clinical applications. His work includes Stanford longevity research and medical product development. BehaVR named him on its scientific advisory board in October 2021. The affiliation is historical and does not establish a current term or investment.

Compliance analyst and office manager at ACT Venture Capital since January 2022. Supports the investment team and limited partner reporting and previously worked at AIB; a qualified financial advisor.

Fund accountant at ACT Venture Capital. Joined its financial control department in 2003 and works on operations across multiple funds.

Works in accounts at ACT Venture Capital. Joined in 2017 and manages accounting and financial operations for the management company.

Financial controller at ACT Venture Capital. Joined its financial control department in 1994 and became controller in 1996, overseeing group reporting, tax and regulatory compliance.

Associate at ACT Venture Capital with investment experience at Enterprise Ireland and ISIF and transaction services experience at Deloitte. A chartered accountant with degrees from University College Cork and University College Dublin and a UCD diploma in artificial intelligence.

Principal at ACT Venture Capital and Kauffman Fellow who sources investments, leads diligence and supports portfolio strategy. Previously founded retail and marketing technology businesses; studied history and politics at UCD and executive finance and venture capital programs.

Principal at ACT Venture Capital responsible for sourcing investments, diligence and portfolio support. Previously worked in Paddy Power Betfair corporate development and financial services; a CFA charterholder and Trinity College Dublin business and economics graduate.

General partner at ACT Venture Capital with prior software operating and business development roles at Misys, Kindle Banking Systems and Kao Infosystems, and experience at Enterprise Ireland. Studied commerce at University College Cork.

Managing partner at ACT Venture Capital, which he joined in 1996 after software engineering and business development roles at EDS. Holds physics and mathematics qualifications from UCD and an MBA from Trinity College Dublin; formerly chaired the Irish Venture Capital Association.

ACT Venture Capital is a Dublin-based venture capital firm founded in 1994 that backs technology companies from early stages through growth. Its portfolio spans AI and machine learning, deep tech, connectivity, energy, health and enterprise software, with investments including Deciphex, Ubotica, Provizio, GridBeyond and Oblivious. John Flynn is managing partner, with general partners Debbie Rennick and John O’Sullivan. The firm reports EUR600 million raised across six funds and 140 companies backed; these figures describe its aggregate history. Its ACT VI announcement identifies a EUR140 million first close and investment tickets from EUR100,000 to EUR10 million. Public portfolio listings include both live investments and exits and do not establish each company’s financing dates or ACT’s individual cash contribution.

Technology investor and general partner at ACT Venture Capital. Previously worked in KPMG corporate finance; holds a law degree from University College Dublin and is a fellow of Chartered Accountants Ireland.

BrainCapture is a Danish medical technology company making EEG more accessible through portable hardware, smartphone-guided recordings and remote neurological interpretation. Its BC-1 system combines a battery-powered amplifier, electrode caps, an app that guides non-specialist healthcare workers through recording, and a cloud platform where specialists can review EEG data. The system supports outpatient, hospital and acute-care settings, including locations with limited access to neurological expertise. Founded in 2019, the company is also developing AI-assisted analysis using its growing EEG datasets. Its current product page reports CE MDR certification, including acute and critical care.

CareLoop Health is a University of Manchester spinout developing digital monitoring and relapse prevention for people living with severe mental illness, initially psychosis. Its smartphone app collects daily patient-reported symptoms and offers self-management resources, while predictive algorithms identify changes from an individual baseline and alert care teams. A clinician dashboard supports monitoring, earlier intervention and integration with care pathways. The company works with NHS and research partners to evaluate and deploy its platform, with the aim of keeping people well in their communities and reducing crisis-driven care. Incorporated in 2021, CareLoop raised GBP 1.8 million in seed funding announced in January 2025.

Understanding Zoe is an Australian company providing an AI-assisted app for neurodivergent adults, children and the people who support them. Its Pip companion helps users organise observations, reports, appointments and support information, identify patterns over time, and prepare practical next steps. Families can invite educators, therapists and other supporters into a shared care network with controlled access to information. Founded by parents with lived experience of neurodivergent family life, the company combines care coordination, personalised guidance and record keeping across home, education and workplace settings. Its app supports organisation and preparation and is not presented as a substitute for professional diagnosis or treatment.

Deciphex is a Dublin-based company founded in 2017 that develops AI-powered digital pathology software and services. Its Diagnexia clinical service connects laboratories with specialist pathologists, while Patholytix supports preclinical pathology and drug safety assessment. Donal O’Shea is founder and CEO. Disclosed financing includes EUR2.3 million equity funding reported in 2019, USD6.2 million Series A reported in 2020, Series B totaling EUR14.4 million after its January 2023 extension, and EUR31 million Series C announced in January 2025. It also disclosed EUR10 million venture debt in 2023 and a EUR15 million Claret facility in October 2025 that includes restructuring of existing financing. Facility size and consortium research grants are distinguished from incremental equity proceeds.

RetiSpec is a Toronto-based medical AI company developing retinal imaging to detect biomarkers associated with Alzheimer’s disease and other neurodegenerative conditions. Its hyperspectral eye imaging and AI algorithms aim to predict brain amyloid burden through a non-invasive eye exam, supporting research into earlier detection and more accessible screening. The company works with clinical and research partners to validate its technology and advance commercialisation. Founded in 2016, RetiSpec’s technology is currently available for research use only; its retinal assessment is not presented as an approved routine diagnostic test.

Verge HealthTech Fund is a Singapore-headquartered venture capital manager backing early-stage healthcare technology companies globally. It invests from pre-seed to Series A in healthcare AI and data analytics, diagnostics, connected medical devices, digital health platforms, digital therapeutics and healthcare software. Its partners and network combine scientific, clinical and operating backgrounds to support validation, regulatory planning and international commercialisation. Founded in 2018, Verge focuses on scalable technologies that improve healthcare access, affordability and efficiency, including underserved populations and low- and middle-income markets.

ViewMind is a neuroscience technology company measuring cognitive function through eye movements and pupil responses during visual tasks. Its headset-based assessments and algorithms turn oculomotor signals into reports on cognitive domains for preventive health, healthcare and research customers. Neuroscan is designed for preventive health and cognitive baselining, while Atlas supports clinical and research applications in selected markets. The company is headquartered in the United States with international operations. In the United States, ViewMind describes Neuroscan as FDA-exempt and intended to assess cognitive function rather than diagnose disease, while Atlas remains investigational and is not intended for clinical use.

Physician and public-health specialist listed in HCC’s external advisory network. The published biography describes Singapore healthcare policy, consulting and system-transformation experience; his existing Verge HealthTech Fund adviser identity is preserved.

M. Lance Patton is president of Topcon Healthcare, Inc., effective April 1, 2026. Previously chief commercial officer, appointed in 2024. Published background includes ophthalmic medical-device and diagnostic commercialization. October 6, 2026 issuer announcement reconfirms president; his existing RetiSpec board role is separate.

Robert N. Weinreb, MD, chairs the Scientific Advisory Board of Amydis. His clinical and scientific work focuses on glaucoma, optic neuropathy, retinal imaging and neuroprotection; he trained at Harvard Medical School and UC San Francisco. Robert N. Weinreb advises Spinogenix on science. His clinical and research work at UC San Diego encompasses ophthalmology, glaucoma, retinal imaging and neuroprotection, alongside existing Amydis and RetiSpec affiliations. Robert N. Weinreb is named a machineMD board member in its current public directory. This matches the UC San Diego ophthalmologist and glaucoma researcher already advising Amydis and Spinogenix; prior portrait and all existing roles preserved. Robert N. Weinreb is a current Iantrek board member and glaucoma clinician/researcher at the Shiley Eye Institute. His prior neurological and ophthalmic scientific affiliations and authentic portrait are preserved.

Tyler Shultz is publicly listed by Fusion Fund as Fusion Expert Network Member (network affiliation). His background includes diagnostics entrepreneurship and ethical innovation. A Stanford-trained biologist and Theranos whistleblower, he co-founded two diagnostic companies. Verge HealthTech Fund’s own sources independently confirm his venture-partner affiliation. Outside affiliations are included as published career context, not independently asserted new employment appointments.

Virologist responsible for the scientific portfolio of Charles River’s biologics testing solutions. Has over thirty years of experience in virus safety testing and virus and prion clearance.

Toxicologist with a master’s degree and preclinical research experience, working on digital innovation and alternatives to animal testing for drug safety assessment.

Toxicologist specializing in lung pharmacology, inhalation risk assessment and organotypic cultures. Earned a doctorate in human lung development at Southampton and an MBA at the Open University.

Leads discovery and environmental sciences studies, including ADME, dermal absorption, pharmacokinetics and endocrine disruption. Earned a doctorate in biomedical research at the University of Amsterdam.

Combinostics is a Finnish medical software company developing AI-assisted imaging analysis and clinical decision support for neurological disorders. Its cNeuro platform quantifies brain MRI and nuclear-medicine images, combines imaging biomarkers with clinical and laboratory data, and helps clinicians assess conditions including dementia and multiple sclerosis. The software supports diagnosis, disease monitoring and research through cloud services and installations for healthcare providers. Founded in 2014, Combinostics was acquired by SyntheticMR in a transaction completed on January 2, 2025 and now operates as part of that medical-imaging group.

Nucu is a Finnish sleep-wellness technology company founded in 2016 in Oulu. Its current Sleep Tracker is designed for children and teens aged 4–18 and uses a contact-free sensor under a mattress topper or fitted sheet to measure breathing, heartbeat, movement and bedroom conditions. A bedside hub and companion app turn those signals into sleep trends and age-specific insights for families, without cameras or wearable devices. The company previously developed a multisensory baby pad combining sounds, vibrations and sensing with origins in neonatal-care research. Nucu describes its current consumer product as a wellness device for general information, rather than a medical device for diagnosing or treating disease.

Miia Kivipelto is a scientific adviser to NeuroVision Imaging’s BrainHealth programme. Dr. Kivipelto is Director of Research, Development, Education and Innovation at Karolinska Institute, in addition to a Karolinska University Hospital Professor. She is also a leader of the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGERS) trial, which studies lifestyle intervention for Alzheimer’s disease. Miia Kivipelto is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Professor of Clinical Geriatrics, Karolinska Institutet Center for Alzheimer Research; Senior Geriatrician and Director for Research and Development of Medical Unit Aging, Karolinska University Hospital. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Joined the Charles River board in October 2019. Former chief financial officer of TIAA with prior finance roles at Wyndham, Cendant, MetLife and Transamerica.

Cancer researcher and former CEO of Memorial Sloan Kettering Cancer Center, serving from 2010 to 2022. Co-founded Agios Pharmaceuticals and joined the Charles River board in December 2022.

Joined the Charles River board in July 2017. Co-founded Rallybio and held research and development leadership roles at Alexion, AstraZeneca and Pfizer.

Former chief information officer at Alexion Pharmaceuticals and a member of the Charles River board.

Joined the Charles River board in May 2025. Has lithium industry leadership experience at Livent and Arcadium and finance experience at FMC and Goldman Sachs.

Joined the Charles River board in January 2024. Has commercial pharmaceutical leadership experience at Novartis and Johnson & Johnson.

Joined Charles River in 1976 and served as CEO from 1992 until retirement in May 2026. Remains a nonexecutive director.

Joined the Charles River board in May 2025. Has biotechnology leadership experience at Rapport Therapeutics, Cerevel and Tiburio.

Physician and scientist who previously served as dean of Duke University School of Medicine. Her research concerns iron metabolism.

Joined the Charles River board in May 2025. Has investment engagement and capital markets experience at Elliott and Goldman Sachs.

Joined Charles River in 2019 after approximately twenty years at IBM. Leads people operations and total rewards.

Joined Charles River in 2017. Previously held finance roles at Bruker and was an Ernst & Young partner.

Joined Charles River in 2008. Trained in veterinary medicine at Glasgow and virology at Louis Pasteur University.

Joined Charles River in 2000 and became chief commercial officer in 2024. Holds an executive MBA from Suffolk University.

Joined Charles River in 2026. Previously held legal leadership positions at Alcon and worked at Sanofi and international law firms.

Joined Charles River in 2001 in Germany. Leads global manufacturing, including biologics and contract development and manufacturing operations.

Joined Charles River as a study director in 2004 and became senior vice president in 2025. Previously worked in FBI microbiology.

Joined Charles River in 2007 and became chief communications officer in 2020. Holds a journalism degree from Northeastern University.

Joined Charles River in 2026 and chairs its scientific advisory board. Previously served as FDA chief scientist and principal deputy commissioner and chaired pharmacology at Johns Hopkins.

Joined Charles River through its 2004 merger with Inveresk. Leads European safety assessment operations.

Joined Charles River in 2000 and became executive vice president in 2022. Leads global discovery and safety assessment.

Joined Charles River in 2021. Previously worked at McKinsey, DoubleClick and Accenture.

Joined Charles River in 2005 and moved into corporate development in 2014. Oversees corporate development and strategy.

Joined Charles River in 2019 and leads its people organization. Previously worked at ITT and IBM.

Joined Charles River in 1989 and became CEO in May 2026 after serving as chief operating officer.

Joined Charles River in April 2026. Previously held finance leadership roles at Premier, Dentsply Sirona and Integra.

Charles River Laboratories is a publicly listed life-sciences research and development services company founded in 1947 and headquartered in Wilmington, Massachusetts. It supports pharmaceutical, biotechnology and academic customers with research models, drug discovery, preclinical safety assessment and manufacturing services. Its neuroscience capabilities include central nervous system discovery services. With Valo Health, it developed Logica, an AI-powered drug-discovery offering, and it made an equity investment in causal AI and digital-twin company Aitia in November 2023. Birgit Girshick became CEO in May 2026; James C. Foster retired from executive leadership and remains a director. Charles River also makes strategic biotechnology investments; recorded investment links reflect verified financing disclosures and are being expanded through portfolio research.

Adamant Health is a Finnish health-technology company providing wearable measurement and analysis of Parkinson’s disease and other movement disorders. Its service combines surface electromyography and motion-sensor data collected during everyday life with software analysis, giving clinicians an objective view of motor symptoms and medication response beyond brief clinic visits. It also serves pharmaceutical companies and research organisations developing and evaluating therapies. Founded in 2020 as a University of Eastern Finland spinout, the company combines neuromuscular research, wearable sensing and AI to support more personalised disease management.

Sooma Medical is a Finnish medical-device company developing portable, non-invasive brain stimulation for depression and chronic pain. Its Sooma tDCS system delivers transcranial direct current stimulation under clinician guidance, while its digital portal supports remote treatment monitoring and adherence. Founded in 2013, Sooma manufactures devices in Finland and supplies healthcare providers and researchers internationally. Its device has European MDR certification; in the United States, Sooma reports Breakthrough Device designation and an Investigational Device Exemption, with devices currently limited to investigational use.

Photoncycle is a Norwegian energy technology company developing seasonal hydrogen storage for homes and businesses. Its system converts surplus renewable electricity into hydrogen, stores it underground in a solid state, and uses a reversible fuel cell to provide heat and electricity when solar production falls. It combines solar generation, long-duration storage and energy trading through a planned subscription model. The company is piloting its technology and preparing commercial deployment in Denmark and the Netherlands, with manufacturing expansion planned from 2027.

Startuplab is a Norwegian incubator, accelerator and pre-seed investor supporting technology startups through offices in Oslo and Bergen, founder programmes, corporate partnerships and venture capital. Its Startuplab Ventures investment unit manages the Founders Funds and invests in first equity rounds, supporting founders with fundraising, valuation, portfolio management and introductions to follow-on investors. The portfolio spans software, AI, industrial hardware, energy and climate technology. Startuplab was founded in 2012 and began venture investing in 2013; Fund V reached a NOK 332 million final close announced in December 2025.

Iya Khalil is a physicist and AI entrepreneur who co-founded GNS Healthcare, now Aitia, with Colin Hill in 2000. She previously served as its chief commercial officer and executive vice president. She earned a physics doctorate at Cornell University. Her later work includes pharmaceutical AI and genome-science leadership; her founder role does not imply a current Aitia executive appointment.

Timothy Thompson is an independent director at Aitia. He previously led Aptus Health, Intervention Insights and Proventys and held business-development leadership roles at Aetna and PHT. He founded Clinical Data Solutions and studied zoology and biochemistry at the University of New Hampshire.

Peter Neupert serves on Aitia’s board, bringing experience in technology, healthcare and corporate governance. He previously held leadership positions at Microsoft and was the founding chief executive of Drugstore.com. He studied at Colorado College and Dartmouth’s Tuck School of Business. Labcorp public biography: Peter M. Neupert Director Peter M. Neupert has served as a director of the Company since January 1, 2013 and previously served as the Board’s lead independent director from July 2019 until June 2023. Mr. Neupert was an Operating Partner at Health Evolution Partners, a health only, middle market private equity firm, from January 2012 until June 2015. Prior to that, Mr. Neupert served as Corporate Vice President of the Microsoft Health Solutions Group from its formation in 2005 to January 2012. Mr. Neupert served on the President George W. Bush’s Information Technology Advisory Committee (PITAC), co-chairing the Health Information Technology Subcommittee and helping to drive the “Revolutionizing Health Care Through Information Technology” report, published in June 2004. Mr. Neupert served as the founding President and Chief Executive Officer of drugstore.com from 1998 to 2001 and as Chairman of the board of directors through September 2004. Mr. Neupert has served as a director of Fortrea Holdings, Inc. since it became publicly traded in June 2023. Mr. Neupert has served as a director of Adaptive Biotechnologies Corporation since December 2013 and currently serves as the Lead Independent Director. He served on the Board of Directors of Quality Systems, Inc., now known as NextGen Healthcare, Inc., from August 2013 to January 2014. He previously served as a trustee for the Fred Hutchinson Cancer Research Center and was an active member of the Institute of Medicine’s Roundtable on Value & Science-Driven Healthcare from 2007 to 2011. Mr. Neupert is an audit committee financial expert as a result of his experience, including his experience as CEO and Chairman of drugstore.com.

David W. Miller is an Aitia board observer and a GHO Capital operating partner with pharmaceutical market-access and health-economics experience. He previously held leadership roles at Biogen, Elan and GlaxoSmithKline. He trained in pharmacy at the University of Iowa and earned a doctorate at the University of Maryland Baltimore.

Joel Krikston is an Aitia board observer and a venture-investment executive at Merck Global Health Innovation Fund. His prior experience includes Johnson & Johnson Development Corporation and healthcare investment banking. He studied finance at Fairfield University and earned an MBA at NYU Stern.

Josh Holden serves on Aitia’s board and co-founded Capital Pulse, a medical-claims valuation and financing business. His prior experience includes OpenDoor, Fina Technologies and trading roles at Goldman Sachs, Deutsche Bank and Countrywide. He holds engineering degrees from MIT.

Craig Cimini is a board observer at Aitia and leads corporate venture investment strategy for The Cigna Group Ventures. His work covers minority investments, partnerships and joint ventures. He studied at Gettysburg College and Cornell University.

Hairong Zhang joined Aitia in 2023 and leads corporate strategy, development and strategic data partnerships. She previously worked in medical-device regulatory affairs and commercial strategy. She holds biomedical engineering and business graduate degrees from Cornell University.

Jerome Windsor leads business development and strategic alliances at Aitia. His experience spans biopharma, payers and digital health, with previous roles at Celata Bioinnovations, Median Technologies, UnitedHealth Group’s i3, Accenture, PwC and GSK. He trained in pharmacy and business.

Joshua Thompson leads Aitia’s software engineering and language-model integration work, including the REFS platform and tools for interpreting causal models. He joined Aitia in 2018 after studying mathematics and computer science at Texas A&M University–Corpus Christi.

Fintan Steele joined Aitia in 2026 to lead scientific and corporate communications. His prior positions include communications leadership at SomaLogic, the Broad Institute and Novartis Institutes for BioMedical Research, as well as scientific publishing. He earned a doctorate in biological sciences at Notre Dame.

So-Youn Shin leads a neuroscience team at Aitia focused on identifying therapies for neurodegenerative diseases. She previously conducted research at the Wellcome Trust Sanger Institute and University of Bristol. She studied at Seoul National University and earned graduate degrees in applied mathematics and statistics at Stony Brook University.

Brenton Paolella joined Aitia in 2026 to lead precision oncology teams and preclinical and clinical programs. He previously led cancer genomics target discovery at Merck Research Labs and worked on the Broad Institute’s Cancer Dependency Map. He earned a doctorate at Dartmouth’s Geisel School of Medicine.

Lyudmila Makowsky leads finance at Aitia. Her previous finance leadership roles include Sensata Technologies, Philips, SGS Life Sciences, Labcorp and Covance, with experience in strategic planning, financial analysis, business integration and governance.

Jeanne Latourelle leads precision medicine at Aitia. Before joining in 2015, she conducted genetic epidemiology research at Boston University, including neurodegenerative disease research. She holds degrees in biomedical engineering, mechanical engineering and epidemiology from Boston University and MIT.

Colin Hill is Aitia’s co-founder and chief executive officer, leading its causal AI and digital-twin drug discovery business. He studied physics at Virginia Tech, McGill and Cornell. His experience includes biotechnology and healthcare board service and developing AI applications for precision medicine.

Jean-Michel Gries is president and chief operating officer of Aitia. His previous leadership positions span Hengenix, Henlius, Kodikaz Therapeutics, Roche, Alcon, Covance and Parexel. His expertise includes clinical pharmacology, translational medicine, drug development and licensing.

Tom Grammatopoulos leads business development and strategy at Aitia, drawing on neuroscience, mitochondrial biology and drug-discovery experience. He previously held leadership roles at iNeuro Therapeutics, Lucy Therapeutics and Charles River Laboratories, and co-founded BioEnergetics. He earned a doctorate in cell and structural biology at the University of Illinois Urbana-Champaign.

Bruce Church develops the REFS algorithms and leads research and technology development at Aitia. A member of its founding team, he previously researched protein-folding optimization at Cornell University, where he earned degrees in engineering physics and applied physics.

Aitia is a Cambridge, Massachusetts biotechnology company using causal artificial intelligence and computational digital twins to discover and develop drugs. Formerly GNS Healthcare, it adopted the Aitia name in January 2023. Its REFS causal modeling platform and Gemini Digital Twins combine multi-omic patient data and high-performance computing to investigate disease mechanisms and therapeutic targets, with work in Alzheimer’s, Parkinson’s and Huntington’s diseases and oncology. Colin Hill is co-founder and CEO, and Jean-Michel Gries is president and COO. Disclosed financing includes an investment from Cambia in 2012, USD10 million Series B in 2014, USD10 million Series C in 2015, separate undisclosed Horizon and Celgene investments in 2016, USD6 million additional equity in 2017 and Series D totaling USD28 million after its 2020 extension. Charles River made an undisclosed equity investment in 2023 alongside a drug-discovery collaboration. Collaboration and licensing agreements are distinguished from equity investments; these disclosures do not establish a complete lifetime funding total.

Monil is a Norwegian agricultural technology company developing virtual fencing and animal-monitoring systems for grazing livestock. Farmers use its mobile app to draw and change grazing boundaries, while solar-powered GPS collars guide animals through audio cues and provide location and activity data. The system supports rotational grazing, remote herd visibility and alerts, with additional analysis of behaviour and potential health changes. Founded in 2022 by engineers with low-power electronics experience, Monil combines collars, embedded software, connectivity and cloud services for cattle farmers in Norway and international markets.

UtilityCloud is a Norwegian SaaS company providing billing and customer information systems for electricity retailers, district heating companies and EV charging providers. Its cloud platform automates customer management, product configuration, settlement, invoicing and collection, with APIs and self-service tools for energy customers. Designed for different energy-market rules and regulatory requirements, it helps retailers run operations across the Nordics and broader Europe. The business was founded in 2019 by energy-industry specialists and combines sector expertise with configurable software rather than bespoke billing projects.

Wenn is a Norwegian technology company developing CarEye, an AI-assisted vehicle inspection system for car rental, airport parking, valet and other mobility operators. Its scanning gates combine structured lighting, high-resolution cameras and machine learning to document a vehicle's exterior as it drives through, creating time-stamped pickup and return records and flagging potential damage. Human reviewers confirm findings before customer-facing decisions or charges. The company provides integrated hardware, software and APIs to make vehicle handovers more consistent and resolve damage disputes using visual evidence.

George Scangos is an Octave Bioscience board director and former CEO of Vir Biotechnology, Biogen and Exelixis. His background includes biotechnology research and management.

Lucy Coassin is an Octave Bioscience board director and a Northpond Ventures investor. Her earlier commercial experience includes Current Health, Science 37, Genentech and Life Technologies. Northpond’s current team lists Lucy Coassin as Director.

Grant Heidrich III is an Octave Bioscience board director. He previously co-led Mayfield’s healthcare investing and served in venture-industry leadership organizations.

Tom Hawes is an Octave Bioscience board director and a healthcare investor associated with Sandbox Industries and the BlueCross BlueShield fund-management team.

Brook Byers is an Octave Bioscience board director and a founding member of Kleiner Perkins. His venture investing career includes building biotechnology and healthcare companies.

William Hagstrom founded Octave Bioscience and serves as its board chair, following his earlier tenure as CEO. His prior leadership experience includes Crescendo Bioscience and Urocor.

Darin Okuda is a senior medical advisor to Octave Bioscience and a UT Southwestern neurology professor. He researches multiple sclerosis, neuroimaging and radiologically isolated syndrome.

Jennifer Graves is a consultant senior medical director at Octave Bioscience and a UC San Diego neurosciences professor. Her research covers multiple sclerosis, biomarkers and wearable assessment.

Erika B. Ortiz directs people operations at Octave Bioscience. Her previous HR leadership roles include Simple Things, Rivian, Nauto and Essential Products.

Jennifer Mellum leads marketing at Octave Bioscience. Her earlier marketing and customer-experience roles include GRAIL, GeneDx, Prime Therapeutics, Risk Management Solutions and Clorox.

Zachary Fernandes leads business development at Octave Bioscience. He previously led diagnostics partnerships at Quanterix and held business development roles at Veritas Genetics and Mission Bio.

David Brazel leads data science at Octave Bioscience, supporting its MSDA platform and biomarker development. He previously worked at Color Health and Sandia National Laboratories.

Terrie Livingston leads medical affairs at Octave Bioscience. Her pharmaceutical and clinical research background includes Pharmacia, Novartis, Biogen and EMD Serono.

Kirk Stockwood leads Octave Bioscience’s commercial activities. His diagnostics and life-sciences experience includes Quanterix, 10x Genomics, Natera and Color Health.

Debbie Ledet leads market access at Octave Bioscience. Her diagnostics and reimbursement experience includes NeoGenomics, Perspectum, Biotheranostics, Natera and Johnson & Johnson.

Marcel Konrad is Octave Bioscience’s CFO. His earlier finance leadership roles include Medexus Pharmaceuticals, CareDx, Santen and Novartis. He is a US CPA.

Doug Biehn is president and CEO of Octave Bioscience and a board director. His previous healthcare leadership roles include Cala Health, iRhythm, McKesson, AliveCor and Blue Shield of California.

Cemit is a Norwegian railway technology company combining onboard sensors, cloud software and AI to monitor the condition of tracks, trains and trams. Its sensors collect vibration data during normal operation and transmit it to the CEMIT Railway Intelligence Platform, which helps operators detect deterioration, investigate changes, schedule maintenance and improve passenger comfort. The platform provides separate insights into infrastructure health and vehicle performance, supporting safer and more efficient railway operations.

Disruptive Technologies is a Norwegian IoT company developing small wireless sensors, connectivity gateways and cloud software for continuous monitoring of buildings, equipment and cold storage. Its low-power devices collect measurements such as temperature, humidity, occupancy and activity, helping customers manage food safety, healthcare assets, workplace usage and energy consumption. Founded in 2013, it combines semiconductor engineering with secure data delivery and application software. Digi International announced an agreement to acquire the company on October 1, 2026; completion remains subject to regulatory approval.